Table 1.
Baseline characteristics.
| Patient characteristics | COVID-19 setting |
||||
|---|---|---|---|---|---|
| Total (N = 252) | Hospital-acquired (N = 47) | Community-acquired (N = 205) | p-value | ||
| Age (year) | Median age | 73 | 69 | 74 | – |
| Range | 4–95 | 36–89 | 4–95 | ||
| Gender - no. (%) | Male | 127 (50) | 26 (55) | 101 (49) | 0.45 |
| Female | 125 (50) | 21 (45) | 104 (50) | ||
| ECOG-PS - no. (%) | 0 | 49 (19) | 6 (13) | 43 (21) | 0.17 |
| 1 | 92 (37) | 22 (47) | 70 (34) | ||
| 2 | 50 (20) | 8 (17) | 42 (20) | ||
| 3 | 27 (11) | 9 (19) | 18 (9) | ||
| 4 | 8 (3) | 1 (2) | 7 (3) | ||
| Unknown | 26 (10) | 1 (2) | 25 (12) | ||
| Cancer type - no. (%) | Lung | 36 (14) | 12 (26) | 24 (12) | – |
| Breast | 34 (13) | 5 (11) | 29 (14) | ||
| Lymphoma | 28 (11) | 5 (11) | 23 (11) | ||
| Prostate | 22 (9) | 4 (9) | 18 (9) | ||
| Colon/colorectal | 20 (8) | 4 (9) | 16 (8) | ||
| Leukaemia | 20 (8) | 2 (4) | 18 (9) | ||
| Gynaecologic | 15 (6) | 3 (6) | 12 (6) | ||
| Multiple myeloma | 11 (4) | 0 | 11 (5) | ||
| Bladder | 8 (3) | 0 | 8 (4) | ||
| Renal cell cancer | 8 (3) | 0 | 8 (4) | ||
| Myeloproliferative neoplasm | 7 (3) | 0 | 7 (3) | ||
| Pancreas | 7 (3) | 2 (4) | 5 (2) | ||
| Esophageal/gastric | 6 (2) | 1 (2) | 5 (2) | ||
| Sarcoma | 5 (2) | 1 (2) | 4 (2) | ||
| Skin cancers | 4 (2) | 1 (2) | 3 (1) | ||
| CNS [2] | 4 (2) | 2 (4) | 2 (1) | ||
| Cholangiocarcinoma | 4 (2) | 2 (4) | 2 (1) | ||
| Thyroid | 4 (2) | 0 | 4 (2) | ||
| Head and neck | 4 (2) | 2 (4) | 2 (1) | ||
| Hepatocellular carcinoma | 2 (0.8) | 0 | 2 (1) | ||
| Mesothelioma | 1 (0.4) | 0 | 1 (0.5) | ||
| Unknown primary | 2 (0.8) | 1 (2) | 1 (0.5) | ||
| Stage - no. (%) | IV/advanced | 106 (42) | 24 (51) | 82 (40) | 0.38 |
| I-III/localized | 90 (36) | 14 (30) | 76 (37) | ||
| Unknown | 56 (22) | 9 (19) | 47 (23) | ||
| Active cancer therapy - no. (%) | No | 146 (58) | 30 (64) | 116 (57) | 0.36 |
| Yes | 106 (42) | 17 (36) | 89 (43) | ||
| Type of cancer therapy - no. (%) | Chemotherapy | 63 (59) | 12 (71) | 51 (57) | 0.44 |
| Targeted | 16 (15) | 1 (6) | 15 (17) | ||
| Anti–PD-1/PD-L1 | 13 (12) | 3 (18) | 10 (11) | ||
| Endocrine | 13 (12) | 1 (6) | 12 (13) | ||
| Smoking history - no. (%) | Active | 26 (10) | 6 (13) | 20 (10) | 0.06 |
| Past | 52 (21) | 5 (11) | 47 (23) | ||
| Never | 85 (34) | 6 (13) | 79 (39) | ||
| Unknown | 89 (35) | 30 (64) | 59 (29) | ||
| RECIST - no. (%) | PD | 34 (13) | 6 (13) | 28 (14) | 0.06 |
| SD | 20 (8) | 1 (2) | 19 (9) | ||
| PR | 13 (5) | 3 (6) | 10 (5) | ||
| CR | 49 (19) | 4 (9) | 45 (22) | ||
| NE [2] | 136 (54) | 33 (70) | 103 (50) | ||
| Comorbid conditions – no. (%) | Pulmonary | 80 (32) | 13 (28) | 67 (33) | 0.58 |
| Cardiac | 78 (31) | 17 (36) | 61 (30) | ||
| Diabetes | 63 (25) | 16 (34) | 47 (23) | ||
| Chronic kidney disease | 47 (19) | 11 (23) | 36 (18) | ||
ECOG-PS, Eastern Cooperative Oncology Group performance status; no., number; CNS, central nervous system.